Synergistic Polygala Extract System for Personalized ADHD Treatment
Legal Citation
Summary of the Inventive Concept
A novel system integrating Radix Polygalae extract with AI, IoT, and blockchain technologies to provide personalized treatment recommendations and optimize ADHD symptom management.
Background and Problem Solved
The original patent disclosed the use of Radix Polygalae extract for treating ADHD, but its efficacy and treatment outcomes varied among individuals. The new inventive concept addresses this limitation by combining the extract with advanced technologies to create a more effective and personalized treatment system.
Detailed Description of the Inventive Concept
The system comprises a wearable device with a biosensor for monitoring physiological data, a mobile application for processing the data and providing personalized treatment recommendations, and an oral composition comprising an effective amount of Radix Polygalae extract. The system uses machine learning algorithms to analyze genomic data and identify genetic markers associated with ADHD, enabling targeted treatment. Additionally, a blockchain-based system tracks the supply chain of Radix Polygalae extract, ensuring authenticity and quality. The system's AI-powered optimization of the extract's composition further enhances therapeutic efficacy.
Novelty and Inventive Step
The new claims introduce the novel combination of Radix Polygalae extract with AI, IoT, and blockchain technologies, which provides a synergistic effect in treating ADHD. This integration enables personalized treatment recommendations, optimized composition, and secure supply chain management, distinguishing the inventive concept from the original patent.
Alternative Embodiments and Variations
Alternative embodiments include using different types of biosensors, integrating with electronic health records, or incorporating additional AI-powered analytics for more accurate treatment recommendations. Variations of the system could target specific ADHD subtypes or be adapted for use in different populations, such as children or adults.
Potential Commercial Applications and Market
The Synergistic Polygala Extract System has significant commercial potential in the ADHD treatment market, which is expected to grow significantly in the coming years. The system's personalized approach and advanced technologies could attract patients seeking more effective and targeted treatments, as well as healthcare providers and payers looking to improve treatment outcomes and reduce costs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K36/69 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K9/485 |
| A | A61 | A61K9/4825 |
| A | A61 | A61K9/4858 |
| A | A61 | A61K47/02 |
| A | A61 | A61K47/12 |
| A | A61 | A61P25/28 |
| A | A61 | A61K2236/333 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, medical device technologies, and digital health systems focused on neurological disorder treatment, specifically ADHD management and personalized medicine interventions
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biomedical engineering, pharmacology, or computer science, possessing expertise in AI-driven medical technologies, biotechnology extraction methods, and digital health platform design
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with botanical extract treatments represents a predictable evolution of personalized medicine approaches. The combination of AI, biosensors, and blockchain with an established ADHD treatment methodology follows standard technological convergence patterns in medical innovation. The PTD's variations demonstrate incremental improvements that would be apparent to a skilled practitioner seeking to enhance treatment precision and patient outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,592 |
|---|---|
| Title | Polygala extract for the treatment of attention-deficit hyperactivity disorder |
| Assignee(s) | BioLite Inc. |